Line Nederby
Impact in
- Hematology top 5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 18
- Acute Myeloid Leukemia Research 11
- Chronic Myeloid Leukemia Treatments 5
- Genetics 12
- Myeloproliferative Neoplasms: Diagnosis and Treatment 7
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Peter HoklandAnne Stidsholt RougAnders JakobsenTorben Frøstrup HansenAnni AggerholmLene Hyldahl EbbesenCharlotte Guldborg NyvoldUffe Birk Jensen
- Journals
- British Journal of Haematology (7 papers)Journal of Clinical Oncology (3 papers)Blood (3 papers)Scientific Reports (2 papers)Journal of Immunological Methods (2 papers)
- Partner nations
- DenmarkUnited KingdomSweden
In The Last Decade
Line Nederby
41 papers receiving 443 citations
Peers
Comparison fields: 5 of 71
- Hematology 204
- Genetics 81
- Immunology 145
- Cancer Research 68
- Oncology 121
Countries citing papers authored by Line Nederby
This map shows the geographic impact of Line Nederby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Line Nederby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Line Nederby more than expected).
Fields of papers citing papers by Line Nederby
This network shows the impact of papers produced by Line Nederby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Line Nederby. The network helps show where Line Nederby may publish in the future.
Co-authors
The 25 scholars most cited alongside Line Nederby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 8 | |
| 2 | 2024 | 3 | |
| 3 | 2023 | 7 | |
| 4 | 2023 | 4 | |
| 5 | 2022 | 1 | |
| 6 | 2021 | 4 | |
| 7 | 2021 | 14 | |
| 8 | 2020 | 22 | |
| 9 | 2020 | 4 | |
| 10 | 2019 | 17 | |
| 11 | 2018 | 2 | |
| 12 | 2017 | 7 | |
| 13 | 2015 | 2 | |
| 14 | 2014 | 11 | |
| 15 | 2014 | 1 | |
| 16 | 2014 | 10 | |
| 17 | 2013 | 1 | |
| 18 | 2011 | 4 | |
| 19 | 2011 | 23 | |
| 20 | 2011 | 16 |
About Line Nederby
Line Nederby is a scholar working on Hematology, Genetics, Immunology, Oncology and Pulmonary and Respiratory Medicine, having authored 42 papers that have together received 445 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (11 papers), Immune Cell Function and Interaction (11 papers), Cancer Immunotherapy and Biomarkers (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Lung Cancer Treatments and Mutations (6 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Lung Cancer Research Studies (4 papers). The work is most often cited by research in Hematology (204 citations), Genetics (81 citations), Immunology (145 citations), Cancer Research (68 citations) and Oncology (121 citations). Line Nederby has collaborated with scholars based in Denmark, United Kingdom and Sweden. Frequent co-authors include Peter Hokland, Anne Stidsholt Roug, Anders Jakobsen, Torben Frøstrup Hansen, Anni Aggerholm, Lene Hyldahl Ebbesen, Charlotte Guldborg Nyvold, Uffe Birk Jensen, Per Guldberg and Marianne Hokland. Their work appears in journals such as British Journal of Haematology, Journal of Clinical Oncology, Blood, Scientific Reports and Journal of Immunological Methods.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.